X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/lillys-lebrikizumab-delayed-fda-clears-eczema-people-skin-color
https://www.ema.europa.eu/en/documents/overview/ebglyss-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-lillys-lebrikizumab-monthly-maintenance-dosing-at-two-years-301962678.html
https://www.fiercepharma.com/pharma/eli-lilly-slapped-third-fda-rejection-2023-time-eczema-treatment-lebrikizumab
https://www.prnewswire.com/news-releases/up-to-73-of-atopic-dermatitis-patients-taking-lillys-lebrikizumab-had-improved-or-cleared-skin-on-face-or-hands-in-new-analysis-301811624.html
https://www.fiercepharma.com/pharma/eli-lilly-committed-gip-class-expects-over-30-billion-2023-revenues-4-new-product-launches
https://www.prnewswire.com/news-releases/lebrikizumab-dosed-every-four-weeks-maintained-durable-skin-clearance-in-lillys-phase-3-monotherapy-atopic-dermatitis-trials-301619590.html
https://endpts.com/lilly-unveils-early-long-term-data-on-eczema-drug-that-could-chip-away-at-dupixent-market/
https://www.prnewswire.com/news-releases/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials-301562237.html
https://www.prnewswire.com/news-releases/lillys-lebrikizumab-combined-with-topical-corticosteroids-showed-significant-improvements-in-disease-severity-for-atopic-dermatitis-301522363.html
https://endpts.com/eli-lilly-fleshes-out-more-phiii-data-for-dupixent-challenger-as-ad-rivalry-heats-up/
https://endpts.com/fda-tees-up-a-snap-review-for-dupixent-as-sanofi-regeneron-hunt-4th-approval-for-megablockbuster/
https://www.prnewswire.com/news-releases/majority-of-patients-treated-with-lebrikizumab-achieved-skin-clearance-in-lillys-pivotal-phase-3-atopic-dermatitis-studies-301510964.html
https://www.healio.com/news/dermatology/20211221/eli-lilly-announces-positive-phase-3-results-for-lebrikizumab-for-atopic-dermatitis
https://investor.lilly.com/news-releases/news-release-details/lillys-lebrikizumab-demonstrated-significant-skin-improvement
https://www.prnewswire.com/news-releases/lillys-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-phase-3-study-301448625.html
https://www.prnewswire.com/news-releases/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens-future-growth-potential-301408065.html
https://www.marketwatch.com/story/eli-lilly-s-lebrikizumab-meets-main-endpoints-in-atopic-dermatitis-lly-271629108962
https://www.pharmatimes.com/news/lebrikizumab_shows_improvements_in_late-stage_eczema_trial_1374926
https://www.prnewswire.com/news-releases/lillys-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-phase-3-trials-301355459.html
https://www.prnewswire.com/news-releases/photocure-announces-regulatory-approval-of-hexvix-in-chile-301355585.html
https://www.fiercebiotech.com/biotech/aslan-hires-kobayashi-to-add-il-13-clinical-trial-expertise
https://www.prnewswire.com/news-releases/lilly-highlights-the-evolution-of-its-dermatology-portfolio-at-annual-american-academy-of-dermatology-meeting-aad-301075242.html
https://investor.lilly.com/news-releases/news-release-details/lilly-and-dermira-present-new-lebrikizumab-phase-2b-clinical
https://endpts.com/leo-pharma-mounts-another-challenge-to-the-eczema-giants-betting-40m-cash-on-a-drug-from-china/
https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-dermira-300984850.html
https://seekingalpha.com/news/3506961-dermira-29-percent-additional-mid-stage-data-dermatitis-med-lebrikizumab
https://www.businesswire.com/news/home/20191009005218/en/Dermira-Announces-Initiation-Phase-3-Program-Evaluating/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.fiercebiotech.com/biotech/almirall-hands-over-50m-for-european-rights-to-dermira-s-dupixent-challenger
https://endpts.com/eyeing-a-500m-peak-sales-pot-almirall-doubles-down-on-lebrikizumab-as-dermira-lines-up-phiii/
https://www.fiercebiotech.com/biotech/aslan-retools-csl-deal-taking-control-would-be-dupixent-rival
https://endpts.com/little-dermiras-shares-zoom-up-on-promising-phiib-atopic-dermatitis-data-but-the-road-ahead-is-ultra-risky-and-flanked-by-giants/
http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2357692
http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2336111
http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2329424
Market Place
Share 
